Highlights in breast cancer at ESMO 2024: KEYNOTE-522

Highlights from ESMO Breast 2024: addressing toxicities in new cancer treatmentsПодробнее

Breast Cancer ESMO 2024 Highlights: Key Studies Discussed NATALEE, KEYNOTE 522, DESTINY-Breast12Подробнее

2024 ESMO East Highlight VideoПодробнее

HER2+ and PIK3DA-mutated breast cancer updates from ESMO Breast 2024Подробнее

Highlights in breast cancer from ESMO 2021Подробнее

ESMO 2024: Highlights and analysisПодробнее

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBCПодробнее

⁠Keynote 522 Updated Results on Overall Survival Benefit with the Perioperative use of PembrolizumabПодробнее

Advancements in metastatic ER+ breast cancer at ESMO Breast 2024Подробнее

MEDSIR inside ESMO 2024 - Highlights Day 3Подробнее

Breast cancer insights from ESMO 2024Подробнее

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 studyПодробнее

ESMO 2024 Bladder Cancer HighlightsПодробнее

Breast and gynecological cancer highlights at ESMO Immuno-Oncology 2022Подробнее

ESMO Breast 2021 highlightsПодробнее

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBCПодробнее

Colorectal cancer highlights at ESMO 2024: CheckMate 8HW and BREAKWATERПодробнее

ESMO 2022 highlightsПодробнее